Last reviewed: June 23, 2026
Last updated: June 23, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated remarkable weight loss results in clinical trials, with patients losing an average of 15-22% of body weight over 68 weeks. However, whether this medication is appropriate for your specific situation depends on multiple factors including your metabolic profile, genetics, and health history. PlexusDx provides personalized semaglutide therapy guided by precision testing to help you achieve sustainable results.
How Semaglutide Works for Weight Loss
Semaglutide operates by mimicking glucagon-like peptide-1 (GLP-1), a natural hormone that regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in your brain, it signals fullness more quickly during meals and reduces cravings between eating occasions. This mechanism is distinct from stimulant-based weight loss drugs and works with your body's existing hunger-regulation system rather than against it.
The medication also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satiety. Clinical data shows that most weight loss occurs in the first 6-12 months, with continued benefits when treatment is maintained. PlexusDx patients using compounded semaglutide from licensed 503A pharmacies experience the same physiological effects as branded versions, with personalized dosing protocols designed to maximize efficacy while minimizing adjustment side effects.
Safety Profile and Side Effects of Semaglutide
Semaglutide has been studied in over 10,000 patients across multiple clinical trials, and the safety data is robust. Common side effects—nausea, vomiting, constipation, and diarrhea—are typically mild to moderate and tend to decrease as your body adjusts during the first 4-8 weeks. Most patients find that slow dose escalation, starting at the lowest effective dose, significantly reduces gastrointestinal discomfort and improves treatment tolerance.
Rare but serious side effects include pancreatitis (inflammation of the pancreas) and gallbladder-related complications, which is why a thorough health screening before starting therapy is essential. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia should not use semaglutide. PlexusDx requires a detailed intake assessment and recommends baseline laboratory testing to identify any contraindications and establish a personalized safety monitoring plan.
Genetic Factors That Influence Semaglutide Response
Not everyone responds to semaglutide with the same degree of weight loss, and genetics play a significant role in this variation. The GLP1R rs6923761 variant, for example, influences how efficiently your GLP-1 receptors bind and respond to semaglutide therapy. Similarly, the GIPR rs1800437 variant affects glucose-dependent insulinotropic polypeptide signaling, which can modify your overall metabolic response and weight loss trajectory.
PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides to identify your unique genetic predispositions across 150+ genetic insights related to appetite regulation, insulin sensitivity, and weight management. This test, available as a $99 add-on after your first month of treatment, allows your PlexusDx clinician to optimize your compound formulation and dosing strategy based on your biology, not just a standard protocol. Patients with certain genetic profiles may benefit more from tirzepatide or a dual-compound GLP-1 approach instead.
Choosing Between Semaglutide Injection and Oral Forms
PlexusDx offers both compounded semaglutide injection and oral semaglutide, each with distinct advantages. Injectable semaglutide typically produces faster and more consistent weight loss because it bypasses first-pass liver metabolism and maintains stable blood levels throughout the week. The injection is administered once weekly, making it convenient for most patients and requiring minimal time for administration.
Oral semaglutide is a viable alternative for patients who prefer to avoid injections or have needle anxiety. However, oral absorption is variable and dependent on stomach pH and food timing, meaning some patients experience less predictable results or require higher doses to achieve the same effect. Both forms from PlexusDx come from licensed 503A compounding pharmacies and cost $149/month for injection (starting price) and $249/month for oral formulations, with your dose able to increase while your price remains the same. Your PlexusDx clinician will help you select the best form based on your lifestyle, response expectations, and treatment goals.
Is Semaglutide Right for You? Key Considerations
Semaglutide is appropriate for adults with a BMI of 30 or higher (or 27+ with weight-related health conditions), but it is not a substitute for healthy eating and movement—it is a tool that makes lifestyle adherence easier by reducing hunger-driven decisions. You should have realistic expectations: weight loss typically stabilizes after 1-2 years, and stopping treatment often results in weight regain. Success requires long-term commitment and integration with dietary and behavioral modifications.
PlexusDx serves all 50 states without requiring insurance, making semaglutide therapy accessible regardless of coverage status. Treatment is HSA/FSA eligible, and there are no membership fees—you pay a flat monthly rate for your chosen medication. During your initial consultation, PlexusDx clinicians evaluate your medical history, current medications, lifestyle, and weight loss goals to determine whether semaglutide or an alternative GLP-1 therapy (such as tirzepatide or a dual-compound formulation) is most appropriate for your clinical profile.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the difference between brand-name Ozempic and PlexusDx compounded semaglutide?
PlexusDx semaglutide is compounded by licensed 503A pharmacies and contains the same active ingredient as brand Ozempic, but at a significantly lower cost starting at $149/month. Compounded versions are not FDA-approved as branded drugs, but they meet the same United States Pharmacopeia (USP) standards for purity and potency. Your PlexusDx clinician monitors your response just as closely as with branded medications.
How much weight can I expect to lose with semaglutide?
Clinical trials show average weight loss of 15-22% of body weight over 68 weeks, though individual results vary based on genetics, adherence, lifestyle factors, and your starting weight. PlexusDx's Precision Peptide Genetic Test can help predict your likely response category and guide whether semaglutide or tirzepatide may be more effective for your genetic profile.
Does PlexusDx require insurance or a membership fee?
No. PlexusDx serves all 50 states without requiring insurance, and there are no membership fees. Treatment is HSA/FSA eligible, and you pay a flat monthly rate for your medication—your dose may increase, but your price won't.
What happens if I stop taking semaglutide?
Most patients experience gradual weight regain within 1-2 years of stopping semaglutide, as appetite hormones return to baseline and hunger cues intensify. For this reason, semaglutide is considered a long-term maintenance therapy rather than a short-term intervention. PlexusDx clinicians work with you to develop a sustainable treatment plan and discuss realistic timeline expectations during your initial consultation.
Can the Precision Peptide Genetic Test predict whether semaglutide will work for me?
Yes. PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, MC4R, and 10 other metabolic pathways to identify your genetic predispositions toward GLP-1 response, appetite regulation, and weight loss. This $99 add-on test, available after your first month of treatment, helps your clinician optimize your compound formulation and dosing strategy based on your unique biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Why Is Ozempic Not Helping Me Lose Weight?
Navigating Zepbound Doses: Finding Your Most Effective Path to Weight Loss